2、 披露标准 证券代码：920504 证券简称：博迅生物 公告编号：2026-004 上海博迅医疗生物仪器股份有限公司 关于使用闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 1、 审议情况 上海博迅医疗生物仪器股份有限公司（以下简称"公司"）于 2025 年 3 月 6 日第四届董事会第四次会议，审议通过《关于使用闲置自有资金购买理财产品的 议案》，公司计划使用不超过人民币 7,500 万元暂时闲置的自有资金购买安全性 高、流动性好的理财产品（包括但不限于结构性存款、收益凭证等），在上述额 度内资金可以循环滚动使用，自公司第四届董事会第四次会议审议通过之日起 12 个月内有效。 具体内容详见公司在北京证券交易所指定信息披露平台（www.bse.cn）上披 露的《关于使用闲置自有资金购买理财产品的公告》（公告编号：2025-010）。 根据《北京证券交易所股票上市规则》相关规定，交易的成交金额占上市公 司最近一期经审计净资产的 10%以上且超 ...

Group 1 - The stock of Boshin Bio (920504) increased by 12.53% with a turnover rate of 30.08%, and a total transaction amount of 144 million yuan, showing a volatility of 16.52% [1] - The stock was listed on the exchange due to its turnover rate reaching 30.08%, with a net buying amount of 4.727 million yuan from brokerage seats [2] - The top five brokerage seats accounted for a total transaction of 49.8218 million yuan, with a buying amount of 27.2744 million yuan and a selling amount of 22.5474 million yuan, resulting in a net buying of 4.727 million yuan [2] Group 2 - The largest buying brokerage was Guojin Securities Co., Ltd. Shenzhen Branch, with a buying amount of 10.7214 million yuan, while the largest selling brokerage was Dongfang Caifu Securities Co., Ltd. Xinyang Dongfanghong Avenue Branch, with a selling amount of 5.8820 million yuan [2] - Detailed trading information shows the top five buying and selling brokerages, with significant buying from Guojin Securities and selling from Dongfang Caifu Securities [2]

Group 1 - The report highlights the launch of "ChatGPT Health" by OpenAI, which integrates health-related conversations and connects to electronic medical records, indicating a significant potential market for AI in healthcare [9][12] - The "Artificial Intelligence + Manufacturing" initiative aims to achieve reliable supply of core AI technologies and maintain a leading position in the industry by 2027, with specific targets including the application of 3-5 general large models in manufacturing and the creation of 100 high-quality industrial datasets [12][14] - The report identifies key sectors such as AI healthcare, AI pharmaceuticals, and AI biomanufacturing as focal points for development, proposing measures like building intelligent drug discovery platforms and smart supply chain management systems [16][12] Group 2 - The North Exchange's biopharmaceutical sector saw a weekly increase of 5.85%, with medical devices rising by 7.81%, indicating strong market performance [23][26] - Among the biopharmaceutical companies, 90.48% experienced stock price increases, with notable performers including BeiYikang (+45.1%) and XinGanjian (+10.46%) [33][34] - As of January 9, 2026, there are 15 companies in the biopharmaceutical sector awaiting approval on the North Exchange, with an average projected revenue of 424 million yuan for 2024 [34][38] Group 3 - The report emphasizes the importance of AI in enhancing drug development efficiency and supply chain management, aiming to reduce costs and time in pharmaceutical processes [16][12] - The global AI healthcare market is projected to reach approximately $26.65 billion in 2024, with a compound annual growth rate (CAGR) of 38.8% expected until 2033 [18][17] - The Chinese AI healthcare industry is expected to grow from 97.3 billion yuan in 2023 to 159.8 billion yuan by 2028, reflecting significant growth potential in this sector [18][19]

证券代码：920504 证券简称：博迅生物 公告编号：2026-003 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权现金管理情况 1. 审议情况 上海博迅医疗生物仪器股份有限公司（以下简称"公司"）于 2025 年 3 月 6 日召开了第四届董事会第四次会议，审议通过了《关于使用闲置募集资金进行现 金管理的议案》，同意公司在确保不影响募集资金投资计划正常进行、保证募集 资金安全的前提下，公司拟使用额度不超过人民币 3,800 万元的闲置募集资金进 行现金管理，在上述额度和期限范围内资金可以循环滚动使用，自董事会审议通 过之日起 12 个月内有效，如单笔产品存续期超过前述有效期，则决议的有效期 自动顺延至该笔交易期满之日。 具体内容详见公司在北京证券交易所指定信息披露平台（www.bse.cn）上披 露的《关于使用闲置募集资金进行现金管理的公告》（公告编号:2025-009）。 2. 披露标准 根据《北京证券交易所股票上市规则》相关规定，交易的成交金额占上市公 司最近一期经审计净资产的 10 ...

Group 1 - The report highlights the significant progress in the pharmaceutical and healthcare system reforms during the "14th Five-Year Plan" period, with a focus on grassroots healthcare and urban-rural integration [1][12] - The "15th Five-Year Plan" emphasizes the support for innovative drugs and medical devices, aiming to enhance the healthcare system and promote the development of traditional Chinese medicine [1][17] - The report indicates that the 11th batch of national drug procurement successfully implemented innovative goals, including maintaining clinical stability and quality assurance [1][14] Group 2 - As of December 31, 2025, the total market capitalization of 21 pharmaceutical and biotechnology companies on the North Exchange reached 748.30 billion, reflecting a growth of 45.81% from the beginning of the year [2][20] - The average market capitalization of these companies increased to 35.63 billion, up 38.87% from the previous year [2][21] - The North Exchange's pharmaceutical sector is primarily composed of chemical pharmaceuticals (38.10%), medical devices (28.57%), and biological products (19.05%) [2][31] Group 3 - In 2025, the North Exchange's pharmaceutical and biotechnology sector experienced a year-on-year increase of 37.38%, ranking third among various sectors [3][54] - The report notes that 80.95% of the pharmaceutical companies on the North Exchange saw an increase in their stock prices throughout the year [3][42] - The top-performing companies in terms of stock price growth included JinHao Medical (+174.08%), NuoSiLanDe (+105.64%), and BeiYiKang (+76.39%) [3][45] Group 4 - The report indicates that the North Exchange's pharmaceutical companies had a PE TTM average of 73X by the end of 2025, with a peak of 119X in August [2][34] - The distribution of valuations shows that the North Exchange has a higher proportion of companies with significant losses compared to other exchanges, with 28.57% of companies in the loss category [2][40] - The report highlights that the North Exchange's pharmaceutical sector is characterized by a high concentration of companies in the 100X and above PE TTM range [2][43]

证券代码：920504 证券简称：博迅生物 公告编号：2026-002 上海博迅医疗生物仪器股份有限公司 关于签署战略合作协议的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 协议签署概况 （一）合作背景及目的 随着生物制药、特别是合成生物学领域的迅猛发展，生物制药企业、科研机 构等对生物培养过程的精准性、自动化与智能化需求日益迫切。传统的摇床培养 及静态微生物培养方式，高度依赖人工操作与经验判断，在培养条件控制、过程 监测和结果一致性等方面面临显著挑战。实现培养过程的动态、自适应、无人化 控制与在线智能监测，已成为提升研发效率、保障工艺稳定性、加速产业转化的 关键技术瓶颈。 哈尔滨工业大学自主智能无人系统工信部重点实验室在机器视觉、自主智能 控制、多设备协同及人工智能算法等领域具备深厚的研究基础与前沿技术积累， 尤其在动态系统建模、实时视觉感知与高精度自主控制方面成果显著。这些技术 为突破生物培养过程中"黑箱操作"的现状、实现从"静态培养"到"动态智能 培养"的跨越提供了核心支撑。 本次合 ...

一、 授权委托理财情况 1、 审议情况 上海博迅医疗生物仪器股份有限公司（以下简称"公司"）于 2025 年 3 月 6 日第四届董事会第四次会议，审议通过《关于使用闲置自有资金购买理财产品的 议案》，公司计划使用不超过人民币 7,500 万元暂时闲置的自有资金购买安全性 高、流动性好的理财产品（包括但不限于结构性存款、收益凭证等），在上述额 度内资金可以循环滚动使用，自公司第四届董事会第四次会议审议通过之日起 12 个月内有效。 证券代码：920504 证券简称：博迅生物 公告编号：2026-001 上海博迅医疗生物仪器股份有限公司 关于使用闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 公司董事会已对上海浦东发展银行股份有限公司虹口支行的基本情况、信用 情况及其交易履约能力等进行了必要的调查，本次理财不构成关联交易。 具体内容详见公司在北京证券交易所指定信息披露平台（www.bse.cn）上披 露的《关于使用闲置自有资金购买理财产品的公告》（公告编号：2025-0 ...

Market Overview - The medical device sector experienced a decline of 0.74% on December 29, with Huakang Clean leading the drop [1] - The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1] Top Performers - Meihao Medical (301363) saw a closing price of 25.04, with an increase of 8.30% and a trading volume of 197,100 shares, totaling a transaction value of 482 million yuan [1] - Mailande (688273) closed at 41.73, up 8.22%, with a trading volume of 55,200 shares and a transaction value of 227 million yuan [1] - Kangzhong Medical (688607) closed at 45.80, up 7.23%, with a trading volume of 40,200 shares and a transaction value of 180 million yuan [1] Underperformers - Huakang Clean (301235) closed at 39.21, down 8.54%, with a trading volume of 123,300 shares and a transaction value of 488 million yuan [2] - C Jianxin (688805) closed at 47.16, down 7.26%, with a trading volume of 89,000 shares and a transaction value of 426 million yuan [2] - Furuim Medical (300049) closed at 71.93, down 4.20%, with a trading volume of 66,800 shares and a transaction value of 485 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 565 million yuan from institutional investors, while retail investors experienced a net inflow of 328 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Meihao Medical (301363) had a net outflow of 54.30 million yuan from institutional investors, with retail investors also showing a net outflow of 0.76 million yuan [3] - Jigaofazhan (600807) experienced a net inflow of 44.75 million yuan from institutional investors, while retail investors had a net outflow of 61.29 million yuan [3] - Kangzhong Medical (688626) saw a net inflow of 44.26 million yuan from institutional investors, with retail investors showing a slight net outflow [3]

关于取得 2 项发明专利证书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、基本情况 上海博迅医疗生物仪器股份有限公司（以下简称"公司"）于近日取得国家 知识产权局颁发的 2 项《发明专利证书》，具体情况如下： （一）发明名称：一种培养设备及其防结露方法 专利号：ZL 2022 1 1394873.6 证券代码：920504 证券简称：博迅生物 公告编号：2025-118 上海博迅医疗生物仪器股份有限公司 专利权人：上海博迅医疗生物仪器股份有限公司 授权公告日：2025 年 12 月 2 日 授权公告号：CN 120872081 B 二、对公司的影响 专利申请日：2022 年 11 月 8 日 专利权人：上海博迅医疗生物仪器股份有限公司 授权公告日：2025 年 12 月 2 日 授权公告号：CN 115678766 B （二）发明名称：干燥含有可燃挥发物质的金属粉末的装置的控制系统 专利号：ZL 2025 1 1386605.3 专利申请日：2025 年 9 月 26 日 上述专利证书的取 ...

证券代码：920504 证券简称：博迅生物 公告编号：2025-117 上海博迅医疗生物仪器股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权现金管理情况 1. 审议情况 （一） 本次委托理财产品的基本情况 （二） 使用闲置募集资金进行现金管理的说明 上海博迅医疗生物仪器股份有限公司（以下简称"公司"）于 2025 年 3 月 6 日召开了第四届董事会第四次会议，审议通过了《关于使用闲置募集资金进行现 金管理的议案》，同意公司在确保不影响募集资金投资计划正常进行、保证募集 资金安全的前提下，公司拟使用额度不超过人民币 3,800 万元的闲置募集资金进 行现金管理，在上述额度和期限范围内资金可以循环滚动使用，自董事会审议通 过之日起 12 个月内有效，如单笔产品存续期超过前述有效期，则决议的有效期 自动顺延至该笔交易期满之日。 具体内容详见公司在北京证券交易所指定信息披露平台（www.bse.cn）上披 露的《关于使用闲置募集资金进行现金管 ...